HiMedia Laboratories GmbH, Marie-Curie-Str

Cocos Nucifera (Coconut) Oil, Beeswax, Simmondsia Chinensis (Jojoba) Seed Oil, Ricinus Communis (Castor) Seed Oil, Helianthus Annuus (Sunflower) Seed Oil, Polyethylene, Polyhydroxystearic Acid, Acrylates Copolymer, Ethylhexyl Palmitate, Vanillin, Argania Spinosa Kernel Oil, Astrocaryum Murumuru Seed Butter, Butyrospermum Parkii (Shea) Butter, Oryza Sativa (Rice) Bran Extract, 1,2-Hexanediol, Caprylyl Glycol, Phosphatidylcholine, Tocopherol, Glycine Soja (Soybean) Oil, Tribehenin, Rosmarinus Officinalis (Rosemary) Leaf Extract, Octyldodecanol, Sorbitan Isostearate, Helianthus Annuus (Sunflower) Extract, Silica Dimethyl Silylate, Quaternium-90 Bentonite, Butylene Glycol, Pentylene Glycol, Lactic Acid, Methyl Nicotinate, Propylene Carbonate, Sodium Hyaluronate, Palmitoyl Tripeptide-1, Caffeine, Niacin, Ascorbyl Palmitate, Citric Aci For the latest information, it is recommended to review the ingredient list printed on the packaging of the product prior to usage or consumption

These biomarkers can be used in adjunct to MTT assay for a more accurate prediction of the in vivo response
503A Compounding Pharmacies Limitations on Compounding Copies of Commercial Drugs The SAFE Drugs Act proposes to amend Section 503A of the FDCA to (i) codify the definition of essentially a copy of a commercially available drug product and (ii) prevent compounding pharmacies from compounding more than 20 units per month of any drug that is essentially a copy of a commercially available product unless tailored to an individual patient